More than 25 Years of Archived Biomedical and Pharmacological Records Acessible in Electronic Format

Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that it has added EMBASE® Classic to the Dialog® (File 772) and DataStar® (EM73, EMXX) platforms, providing access to more than 25 years of archived life sciences data available for the first time in electronic format.

EMBASE Classic, produced by Elsevier, includes the bibliographic records originally published in the 43 Excerpta Medica abstract print journals from 1947 through 1973. The fully digitized database is drawn from approximately 3,400 international journal titles, with a focus on European and North American published literature including non-English language articles. EMBASE Classic contains more than 1.8 million records from the biomedical and pharmacological literature. The historical data in EMBASE Classic, combined with up-to-date records in the EMBASE database (File 73/EMZZ), gives researchers approximately 60 years of information regarding medical and drug-related subjects.

"With EMBASE Classic, researchers can now review advancements made during an extremely fertile period for the sciences, particularly in the areas of molecular biology, marine sciences, vaccines and other drug therapies," said Geoffrey Dick, Director of Publisher Management, Thomson Scientific. "The archived literature should prove invaluable in reviews of toxicology, adverse events and prior art for patent prosecution."

EMBASE Classic enhances research in:

  • Drug development
  • Pipeline intelligence
  • Designing and mounting clinical investigations
  • New uses for old drugs
  • Approved uses for drugs
  • Adverse events and reactions monitoring on old drugs or endogenous compounds
  • Preparation of new drug applications
  • Product safety and compliance monitoring

EMBASE Classic significantly expands the collection of biomedical and pharmacological literature sought by research professionals. The new database complements current Dialog and DataStar life sciences offerings, including EMBASE® (1974+ in File 73/EMZZ), as well as the recently added BIOSIS Previews® (File 5/BIOL), Zoological Record Online® and MEDLINE (1951+ in File 155/MEZZ) archive data.

For more information about the EMBASE Classic database on Dialog and DataStar, visit www.dialog.com/embaseclassic.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...